Cart
sales@molnova.com
AGI-5198
CAS No. 1355326-35-0
AGI-5198 ( (IDH-C35) )
Catalog No. M11453 CAS No. 1355326-35-0
AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 32 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 37 | In Stock |
|
| 50MG | 43 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAGI-5198
-
NoteResearch use only, not for human use.
-
Brief DescriptionAGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
-
DescriptionAGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms(IDH-C35)
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorR132C-IDH1| R132H-IDH1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1355326-35-0
-
Formula Weight462.57
-
Molecular FormulaC27H31FN4O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 14 mg/mL (30.26 mM); DMSO: 24 mg/mL (51.88 mM)
-
SMILESO=C(NC1CCCCC1)C(N(C2=CC=CC(F)=C2)C(CN3C=CN=C3C)=O)C4=CC=CC=C4C
-
Chemical NameN-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Rohle D, et al. Science, 2013, 340(6132), 626-630.
molnova catalog
related products
-
D-Mannitol
D-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
-
Methotrexate disodiu...
Methotrexate disodium is an tetrahydrofolate dehydrogenase inhibitor.
-
BI-4916
BI-4916 is a selective phosphoglycerate dehydrogenase (PHGDH) inhibitor that inhibits SSP and reduces the migration of cancer cells.BI-4916 can be used in the study of cancer and metabolic diseases.
